BAX326 (RIXUBIS): a novel recombinant factor IX for the control and prevention of bleeding episodes in adults and children with hemophilia B
Abstract: Hemophilia B management has improved considerably since the introduction of high-purity plasma-derived factor IX (pdFIX) products in the early 1990s. Recombinant FIX (rFIX) was introduced more recently and has potential safety advantages over the older bloodbased products. Until recently,...
- Autores:
-
Solano Trujillo, María Helena
Windyga, Jerzy
Hafeman, Andrea E.
- Tipo de recurso:
- Article of journal
- Fecha de publicación:
- 2014
- Institución:
- Fundación Universitaria de Ciencias de la Salud - FUCS
- Repositorio:
- Repositorio Digital Institucional ReDi
- Idioma:
- eng
- OAI Identifier:
- oai:repositorio.fucsalud.edu.co:001/3170
- Acceso en línea:
- https://repositorio.fucsalud.edu.co/handle/001/3170
- Palabra clave:
- Health-related quality of life
Hemophilia B
Pediatric
Pharmacokinetics
Prophylaxis
Recombinant factor IX
Safety
Surgery
Hemofilia B
Calidad de vida
Pediatría
Farmacocinética
Factor IX
Seguridad
Cirugía
- Rights
- openAccess
- License
- Atribución-NoComercial-SinDerivadas 4.0 Internacional (CC BY-NC-ND 4.0)